Victor, MT, United States of America

Kim J Hasenkrug

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovations of Kim J. Hasenkrug

Introduction

Kim J. Hasenkrug, an esteemed inventor based in Victor, Montana, has made significant contributions to the field of medical science through his innovative patents. With a total of five patents attributed to his name, Hasenkrug focuses on groundbreaking therapies targeting infectious diseases, showcasing a strong commitment to advancing healthcare.

Latest Patents

Among Hasenkrug's latest contributions are his patents related to CD47 targeted therapies for the treatment of infectious diseases. These methods provide novel approaches for treating subjects with intracellular pathogen infections. Specifically, they involve administering an agent that reduces the binding of CD47 on an infected cell to SIRPα on a host phagocytic cell. The effective dosage administered aims to enhance the phagocytosis of infected cells, which represents a significant breakthrough in therapeutic strategies against these stubborn infections.

Career Highlights

Throughout his career, Hasenkrug has been affiliated with prestigious academic institutions such as Leland Stanford Junior University and the University of California. His extensive research and dedication to the field have positioned him as a prominent figure in the development of innovative medical treatments.

Collaborations

Kim J. Hasenkrug has collaborated with several esteemed colleagues in his research endeavors, including Kipp Andrew Weiskopf and Cheryl A. Stoddart. These collaborations not only highlight his ability to work in diverse team settings but also underline the collective effort that drives innovation in medical science.

Conclusion

In summary, Kim J. Hasenkrug stands out as a noteworthy inventor whose work in CD47 targeted therapies demonstrates the intersection of innovative thought and practical application in treating infectious diseases. His collaborations and associations with leading research institutions further enhance his contributions, paving the way for future advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…